Evidence review / Questions, answered with citations
TB-500 FAQ: Side Effects, Safety Signals, Legality, and the Evidence
Direct answers to the most-asked TB-500 questions — each graded against the published record and linked to its proof.
TB-500 Side Effects and Safety Signals in the Literature
TB-500 side effects are not characterized in any completed controlled human trial of the fragment, so this section reports the relevant human safety data (which are for the full-length protein) and the standing safety signals rather than a confirmed adverse-event profile [6]. The two enduring concerns are the tumor and angiogenesis signal and the purity of unregulated material; both are answered in full below, alongside the legality and mechanism questions.
What Are the Side Effects of TB-500?
No completed controlled human trial of the TB-500 fragment characterizes its side-effect profile [6]. The relevant human safety data are for intravenous full-length thymosin beta-4, which was well tolerated to 1260 mg with only infrequent mild-to-moderate events and no dose-limiting toxicities [6]. The standing safety concerns are the tumor and angiogenesis signal and the unregulated-material purity problem, not a documented human adverse-event list for the seven-mer.
Does TB-500 Cause Cancer or Promote Tumor Growth?
Thymosin beta-4 is overexpressed in several cancers, including pancreatic and colorectal, and is implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [5]. This is an unresolved safety concern, not a demonstrated human risk for the fragment. It is the single hardest caveat in the record and is the reason the angiogenesis question is treated as a safety matter, not only a mechanism.
Is the Product Purity of Research-Grade TB-500 Reliable?
Identity, purity, and correct sequence — full-length protein versus seven-mer fragment — are not guaranteed in unregulated supply. This is a recurring concern that also complicates interpreting anecdotal results, since a product may not be what its label claims [7]. Analytical reference work has been published to characterize TB-500 preparations precisely, including the synthesis and characterization of the acetylated 17-23 fragment and later UHPLC-Orbitrap methods [8][14].
What Is TB-500 Used For in Research?
Preclinical and topical research on TB-500 and full-length thymosin beta-4 spans wound healing, muscle and ligament repair, cardiac protection, angiogenesis, neurological recovery and hair-follicle biology [5]. No completed controlled human trial of the fragment exists for any indication [6]. The research uses are mechanistic and model-based; they are not approved human applications.
Does TB-500 Work for Muscle Tears and Recovery?
Muscle-injury-induced thymosin beta-4 acts as a chemoattractant for myoblasts in animal models, the basis of the recovery rationale [5]. The honest counterpoint is a null functional result: in dystrophin-deficient mdx mice, six months of thymosin beta-4 increased regenerating fibers but did not improve muscle strength or cardiac function. Histological change without functional gain is a real and instructive negative finding.
Are There Human Clinical Trials on TB-500?
There are no completed controlled clinical trials of the TB-500 heptapeptide for any indication [6]. Human data exist only for full-length thymosin beta-4: a randomized, placebo-controlled Phase 1 intravenous safety study (well tolerated to 1260 mg) and topical ophthalmic RCTs [6]. Some injectable thymosin beta-4 trials were registered, but the efficacy of the seven-mer in humans remains unproven [6].
How Does TB-500 Work?
Full-length thymosin beta-4 binds monomeric (G-) actin 1:1, capping both ends of the monomer to buffer a pool of unpolymerized actin and regulate cytoskeletal dynamics, cell migration and motility [1]. The LKKTETQ region in TB-500 is this actin-binding core [5]. Whether the isolated seven-mer reproduces the full protein's effects is not established in controlled human trials [5].
Can TB-500 Help with Tendon and Ligament Repair?
Thymosin beta-4 enhanced healing of medial collateral ligament injury in a rat model, one of the few direct connective-tissue repair findings underpinning the athletic-recovery rationale [5]. Human ligament and tendon evidence for the fragment is absent [6]. The connective-tissue case rests on animal data, not on any controlled human result.
Does TB-500 Affect the Heart?
In mice, thymosin beta-4 formed a complex with PINCH and integrin-linked kinase that activated Akt, promoted cardiac cell migration and survival, and improved cardiac function after coronary artery ligation [2]. Counter-evidence exists: systemic thymosin beta-4 failed to attenuate ischemia-reperfusion injury in a porcine study. The cardiac record is promising in mice and unconfirmed beyond preclinical models.
Does TB-500 Promote Angiogenesis, and Is That a Concern?
Thymosin beta-4 is associated with endothelial migration and pro-angiogenic signaling [5]. Angiogenesis aids tissue repair but is also a recognized safety consideration, because the same pro-angiogenic, pro-migratory activity could in principle support tumor progression [5]. The benefit and the risk share one mechanism, which is why this site reports angiogenesis as both a repair pathway and a safety signal.
Does TB-500 Have Neuroprotective Effects?
In rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 improved neurological function at 2 and 12 mg/kg, but 18 mg/kg gave no significant benefit — a non-monotonic dose response with a modeled optimum near 3.75 mg/kg [4]. The findings are preclinical, and the non-monotonic curve cautions directly against assuming higher doses help [4].
Does TB-500 Increase Hair Growth?
Thymosin beta-4 at nanomolar concentrations stimulated hair growth in rats and mice by activating hair-follicle bulge stem cells and increasing their migration and differentiation [11]. Independent mouse studies corroborate hair-growth promotion [11]. Human hair-growth efficacy for the fragment is unproven.
Does TB-500 Reduce Inflammation?
Full-length thymosin beta-4 is reported to suppress NF-κB signaling and IL-8 in vitro and is released by platelets and macrophages after injury to limit apoptosis and inflammation [5]. These are preclinical mechanistic observations, largely for the full-length protein rather than the fragment [5].
How Long Does TB-500 Take to Work in Healing Models?
In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline [3]. Timelines are model-specific, and no validated human onset data exist for the fragment [6]. A figure from a rat wound is not a human timeline.
Is TB-500 FDA Approved?
No. TB-500 is not approved by the FDA for human use and has no approved therapeutic indication [17]. FDA reviewed peptide bulk drug substances, including the thymosin beta-4 LKKTETQ fragment, for compounding and flagged safety concerns, placing TB-500 in 503A Category 2 [16][17]. Full detail is on the legal-status page.
Is TB-500 Banned by WADA?
Yes. The World Anti-Doping Agency prohibits TB-500 and thymosin beta-4 under prohibited peptide, growth-factor and tissue-repair categories, banned in and out of competition for the relevant classes [15]. It is detected by LC-MS anti-doping assays in human and equine matrices [7][14].